| Code | CSB-RA006044MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to BC-006, targeting the colony-stimulating factor 1 receptor (CSF1R), also known as CD115 or M-CSFR. CSF1R is a cell surface tyrosine kinase receptor that plays a critical role in the differentiation, proliferation, and survival of mononuclear phagocytes, including macrophages and microglia. Upon binding its ligands CSF1 and IL-34, CSF1R activates signaling pathways that regulate immune cell function and tissue homeostasis. Dysregulated CSF1R signaling is implicated in various pathological conditions, including tumor-associated macrophage recruitment in cancer, inflammatory disorders, and neurodegenerative diseases where microglial activation contributes to pathology.
BC-006 is a investigational monoclonal antibody targeting CSF1R. As an inhibitor of CSF1R, BC-006 blocks CSF1R's binding to CSF1, inhibiting the survival, proliferation and function of tumor-associated macrophages, thereby altering the tumor immune microenvironment and potentially enhancing anti-tumor immunity or directly suppressing tumors. This biosimilar provides researchers with a reliable tool for studying macrophage biology, tumor microenvironment dynamics, neuroinflammation, and CSF1R-mediated signaling mechanisms. It serves as a valuable reagent for exploring therapeutic strategies targeting the CSF1/CSF1R axis in oncology and inflammatory disease research.
There are currently no reviews for this product.